公开(公告)号：WO2006053252A3

公开(公告)日：2006-05-18

申请号：PCT/US2005/041037

申请日：2005-11-14

Applicant: SOPHERION THERAPEUTICS, INC. ,  GHIAS, Kulsoom ,  MA, Chunguang ,  GANDHI, Varsha ,  PLATANIAS, Leonidas, C. ,  KRETT, Nancy, L. ,  ROSEN, Steven, T.

Inventor： GHIAS, Kulsoom ,  MA, Chunguang ,  GANDHI, Varsha ,  PLATANIAS, Leonidas, C. ,  KRETT, Nancy, L. ,  ROSEN, Steven, T.

IPC: A01N43/04 ,  A61K31/70 ,  A61K49/00

Abstract: The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof. Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening candidate drugs for efficacy in treating hematological malignancies.

公开(公告)号：WO2010118265A1

公开(公告)日：2010-10-14

申请号：PCT/US2010/030441

申请日：2010-04-08

Applicant: SOPHERION THERAPEUTICS, INC. ,  ROZENCWEIG, Marcel ,  GOLDFARB, Ronald ,  FORENZA, Salvatore

Inventor： ROZENCWEIG, Marcel ,  GOLDFARB, Ronald ,  FORENZA, Salvatore

IPC: A61K9/127 ,  A61K31/337 ,  A61K31/7036 ,  A61K39/395

CPC classification number: A61K31/7036 ,  A61K9/0019 ,  A61K9/127 ,  A61K31/337 ,  A61K31/704 ,  A61K39/39533 ,  A61K39/39558 ,  A61K47/26 ,  A61K2300/00

Abstract: The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.

Abstract translation: 本发明涉及一种用于治疗个体中转移性乳腺癌的方法，其包括对有需要的个体施用给药方案，其包括向个体非聚乙二醇化脂质体多柔比星，紫杉烷和HER2 / neu受体拮抗剂施用，其中先前个体 已经给予蒽环类药物。

公开(公告)号：WO2006053252A2

公开(公告)日：2006-05-18

申请号：PCT/US2005041037

申请日：2005-11-14

Applicant: SOPHERION THERAPEUTICS INC ,  GHIAS KULSOOM ,  MA CHUNGUANG ,  GANDHI VARSHA ,  PLATANIAS LEONIDAS C ,  KRETT NANCY L ,  ROSEN STEVEN T

Inventor： GHIAS KULSOOM ,  MA CHUNGUANG ,  GANDHI VARSHA ,  PLATANIAS LEONIDAS C ,  KRETT NANCY L ,  ROSEN STEVEN T

IPC: A61K31/7076

CPC classification number: A61K31/7076

Abstract: The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof. Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening candidate drugs for efficacy in treating hematological malignancies.

Abstract translation: 本发明提供了用8-氨基 - 腺苷及其变体治疗血液恶性肿瘤（包括耐多药耐药恶性肿瘤）的方法。 本发明还包括预测诊断患有血液恶性肿瘤的患者对用核苷类似物进行治疗的反应的方法以及筛选候选药物以治疗血液恶性肿瘤的功效的方法。

公开(公告)号：WO2003104415A3

公开(公告)日：2003-12-18

申请号：PCT/US2003/017949

申请日：2003-06-05

Applicant: SOPHERION THERAPEUTICS, INC.

Inventor： ASHKAR, Samy

IPC: G01N33/566

Abstract: Methods and compositions for the screening and identification of ligands that are expressed and displayed on the outer surface of eukaryotic cells and screening for binding of the ligand to a receptor domain of a chimeric fusion receptor protein which is also expressed and displayed on the surface of the cells have been developed. Binding to the receptor domain activates, inhibits, or modulates the enzymatic function of the receptor intracellular domain of the fusion protein.

公开(公告)号：WO2006015385A3

公开(公告)日：2006-05-04

申请号：PCT/US2005027883

申请日：2005-08-05

Applicant: SOPHERION THERAPEUTICS INC ,  RASTELLI LUCA ,  LESCOE MARY K ,  CORSO MELISSA ,  KITSON RICHARD ,  LANDIN JUDITH ,  SOUAN LINA ,  MALYANKAR URIEL M

Inventor： RASTELLI LUCA ,  LESCOE MARY K ,  CORSO MELISSA ,  KITSON RICHARD ,  LANDIN JUDITH ,  SOUAN LINA ,  MALYANKAR URIEL M

IPC: A61K38/04

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K7/08

Abstract: Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases and skin disorders.

Abstract translation: 公开了抑制VEGF介导的内皮细胞活化或增殖的抗血管生成肽。 这些肽可以用于抑制VEGF与VEGFR2受体（也称为激酶结构域受体或KDR）的结合。 这样的肽还可以用于在血管发生相关疾病如癌症，炎性疾病，眼部疾病和皮肤病中抑制VEGF介导的内皮细胞激活。

公开(公告)号：WO2006044614A3

公开(公告)日：2006-04-27

申请号：PCT/US2005/036959

申请日：2005-10-14

Applicant: SOPHERION THERAPEUTICS, INC. ,  RASTELLI, Luca ,  LANDIN, Judith ,  MALYANKAR, Uriel ,  KISTON, Richard ,  CORSO, Melissa ,  BRUNSON, Kenneth

Inventor： RASTELLI, Luca ,  LANDIN, Judith ,  MALYANKAR, Uriel ,  KISTON, Richard ,  CORSO, Melissa ,  BRUNSON, Kenneth

IPC: A61K38/00

Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.

公开(公告)号：WO2006044614A2

公开(公告)日：2006-04-27

申请号：PCT/US2005036959

申请日：2005-10-14

Applicant: SOPHERION THERAPEUTICS INC ,  RASTELLI LUCA ,  LANDIN JUDITH ,  MALYANKAR URIEL ,  KISTON RICHARD ,  CORSO MELISSA ,  BRUNSON KENNETH

Inventor： RASTELLI LUCA ,  LANDIN JUDITH ,  MALYANKAR URIEL ,  KISTON RICHARD ,  CORSO MELISSA ,  BRUNSON KENNETH

IPC: A61K38/54

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K47/62 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001

Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.

Abstract translation: 公开了抑制内皮细胞活化或增殖的抗血管生成肽。 这样的肽可以用于抑制VEGF结合VEGFR2受体（也称为激酶结构域受体或KDR）和bFGF与其受体的结合。 这些肽也可用于抑制血管生成相关疾病如癌症，白血病，多发性骨髓瘤，炎性疾病，眼睛疾病和皮肤疾病中的VEGF，bFGF或整合素激活内皮细胞。

公开(公告)号：WO2006015385A2

公开(公告)日：2006-02-09

申请号：PCT/US2005/027883

申请日：2005-08-05

Applicant: SOPHERION THERAPEUTICS, INC. ,  RASTELLI, Luca ,  LESCOE, Mary, K. ,  CORSO, Melissa ,  KITSON, Richard ,  LANDIN, Judith ,  SOUAN, Lina ,  MALYANKAR, Uriel, M.

Inventor： RASTELLI, Luca ,  LESCOE, Mary, K. ,  CORSO, Melissa ,  KITSON, Richard ,  LANDIN, Judith ,  SOUAN, Lina ,  MALYANKAR, Uriel, M.

IPC: A61K38/17

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K7/08

Abstract: Anti-angiogenic peptides that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR). Such peptides may also be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases and skin disorders.

Abstract translation: 公开了抑制VEGF介导的内皮细胞活化或增殖的抗血管生成肽。 这样的肽可以用于抑制VEGF结合VEGFR2受体（也称为激酶结构域受体或KDR）。 这样的肽也可以用于抑制VEGF介导的血管生成相关疾病如癌症，炎症性疾病，眼睛疾病和皮肤病中内皮细胞的活化。

公开(公告)号：WO2003104415A2

公开(公告)日：2003-12-18

申请号：PCT/US2003/017949

申请日：2003-06-05

Applicant: SOPHERION THERAPEUTICS, INC.

Inventor： ASHKAR, Samy

IPC: C12N

CPC classification number: C07K14/7153 ,  A61K38/00 ,  C07K14/505 ,  C07K14/52 ,  C07K2319/00 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/5064 ,  G01N33/566 ,  G01N2510/00

Abstract: Methods and compositions for the screening and identification of ligands that are expressed and displayed on the outer surface of eukaryotic cells and screening for binding of the ligand to a receptor domain of a chimeric fusion receptor protein which is also expressed and displayed on the surface of the cells have been developed. Binding to the receptor domain activates, inhibits, or modulates the enzymatic function of the receptor intracellular domain of the fusion protein.

Abstract translation: 用于筛选和鉴定在真核细胞的外表面上表达和显示的配体的筛选和鉴定，并筛选配体与嵌合融合受体蛋白的受体结构域的结合，其也表达并显示在 细胞已经开发。 与受体结构域结合激活，抑制或调节融合蛋白受体细胞内结构域的酶功能。